Co-Diagnostics Joint Venture CoSara Receives CDSCO License to Manufacture PCR Pro Instrument in India

Reuters

02/05

Co-Diagnostics Joint Venture CoSara Receives CDSCO License to Manufacture PCR Pro Instrument in India

Co-Diagnostics Inc. announced that its joint venture, CoSara Diagnostics Pvt. Ltd. (CoSara), has received a license from the Central Drugs Standard Control Organization (CDSCO) to manufacture the CoSara PCR Pro™ real-time PCR point-of-care instrument at its facility in Ranoli, India. The CDSCO license, issued on Form MD-5, authorizes the manufacturing and sale or distribution of the CoSara-branded Class A medical device instrument. This represents the final instrument license required by CDSCO before commercialization can begin. CoSara PCR test kits to be used with the instrument, such as those for Mycobacterium tuberculosis $(MTB)$ and human papillomavirus (HPV), require separate regulatory clearance and are not yet available for sale.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Co-Diagnostics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA80385) on February 05, 2026, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2609306504"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2609306504\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2609306504?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-05 22:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609306504","market":"nz","top_or_hot":-1,"title":"Co-Diagnostics Joint Venture CoSara Receives CDSCO License to Manufacture PCR Pro Instrument in India","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Co-Diagnostics Joint Venture CoSara Receives CDSCO License to Manufacture PCR Pro Instrument in India\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Co-Diagnostics Inc. announced that its joint venture, CoSara Diagnostics Pvt. Ltd. (CoSara), has received a license from the Central Drugs Standard Control Organization (CDSCO) to manufacture the CoSara PCR Pro™ real-time PCR point-of-care instrument at its facility in Ranoli, India. The CDSCO license, issued on Form MD-5, authorizes the manufacturing and sale or distribution of the CoSara-branded Class A medical device instrument. This represents the final instrument license required by CDSCO before commercialization can begin. CoSara PCR test kits to be used with the instrument, such as those for Mycobacterium tuberculosis <a href=\"https://laohu8.com/S/MTB\">$(MTB)$</a> and human papillomavirus (HPV), require separate regulatory clearance and are not yet available for sale.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Co-Diagnostics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA80385) on February 05, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Co-Diagnostics Joint Venture CoSara Receives CDSCO License to Manufacture PCR Pro Instrument in India</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCo-Diagnostics Joint Venture CoSara Receives CDSCO License to Manufacture PCR Pro Instrument in India\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2026-02-05 22:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Co-Diagnostics Joint Venture CoSara Receives CDSCO License to Manufacture PCR Pro Instrument in India\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Co-Diagnostics Inc. announced that its joint venture, CoSara Diagnostics Pvt. Ltd. (CoSara), has received a license from the Central Drugs Standard Control Organization (CDSCO) to manufacture the CoSara PCR Pro™ real-time PCR point-of-care instrument at its facility in Ranoli, India. The CDSCO license, issued on Form MD-5, authorizes the manufacturing and sale or distribution of the CoSara-branded Class A medical device instrument. This represents the final instrument license required by CDSCO before commercialization can begin. CoSara PCR test kits to be used with the instrument, such as those for Mycobacterium tuberculosis <a href=\"https://laohu8.com/S/MTB\">$(MTB)$</a> and human papillomavirus (HPV), require separate regulatory clearance and are not yet available for sale.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Co-Diagnostics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA80385) on February 05, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4568","symbol_name":"美國抗疫概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDLDfdBs:1","article_id":"2609306504","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2609306504","pubTimestamp":1770300105,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Co-Diagnostics Inc. announced that its joint venture, CoSara Diagnostics Pvt. Ltd. , has received a license from the Central Drugs Standard Control Organization  to manufacture the CoSara PCR Pro real-time PCR point-of-care instrument at its facility in Ranoli, India. The CDSCO license, issued on Form MD-5, authorizes the manufacturing and sale or distribution of the CoSara-branded Class A medical device instrument. This represents the final instrument license required by CDSCO before commercialization can begin. CoSara PCR test kits to be used with the instrument, such as those for Mycobacterium tuberculosis  and human papillomavirus , require separate regulatory clearance and are not yet available for sale.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investme","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4568":"美国抗疫概念","BK4082":"医疗保健设备","CODX":"Co-Diagnostics, Inc."},"translate_title":"Co-Diagnostics合资企业CoSara获得CDSCO许可在印度生产PCR Pro仪器","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CODX":0.9},"content_text":"Co-Diagnostics Joint Venture CoSara Receives CDSCO License to Manufacture PCR Pro Instrument in India\n    \n\n        Co-Diagnostics Inc. announced that its joint venture, CoSara Diagnostics Pvt. Ltd. (CoSara), has received a license from the Central Drugs Standard Control Organization (CDSCO) to manufacture the CoSara PCR Pro™ real-time PCR point-of-care instrument at its facility in Ranoli, India. The CDSCO license, issued on Form MD-5, authorizes the manufacturing and sale or distribution of the CoSara-branded Class A medical device instrument. This represents the final instrument license required by CDSCO before commercialization can begin. CoSara PCR test kits to be used with the instrument, such as those for Mycobacterium tuberculosis $(MTB)$ and human papillomavirus (HPV), require separate regulatory clearance and are not yet available for sale.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Co-Diagnostics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA80385) on February 05, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}